Product candidate
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3 / pivotal
2022 Milestones
PD-1 Refractory Melanoma
Re-challenge combination w/anti PD-1
ONCOS-102
Mesothelioma
Combination w/Standard-of-Care (SoC)
Multiple Myeloma
TG01 / QS-21
Mutant KRAS
Undisclosed indication
TG01 / QS-21
circular RNA
Cancer Indication:
PD-1 Refractory Melanoma
Combination with: Re-challenge combination w/anti PD-1
Product candidate: ONCOS-102
Next expected event: 4Q 2022 / 1Q 2023
Initiation of multi-cohort phase 2 trial
Combination with: Re-challenge combination w/anti PD-1
Product candidate: ONCOS-102
Next expected event: 4Q 2022 / 1Q 2023
Initiation of multi-cohort phase 2 trial
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication:
Mesothelioma
Combination with: Combination w/Standard-of-Care (SoC)
Product candidate: ONCOS-102
Next expected event: 1H 2022
Full study data presented at ASCO, incl. 30 month OS rate
Combination with: Combination w/Standard-of-Care (SoC)
Product candidate: ONCOS-102
Next expected event: 1H 2022
Full study data presented at ASCO, incl. 30 month OS rate
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication:
Multiple Myeloma
Combination with: TG01 / QS-21
Product candidate: Mutant KRAS
Next expected event: 2H 2022
First patient visit (EU)
Combination with: TG01 / QS-21
Product candidate: Mutant KRAS
Next expected event: 2H 2022
First patient visit (EU)
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3 / pivotal